{"entity":{"id":"nct04446117","kind":"trial","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","aka":["CONTACT-02"],"tldr":"A phase 3 trial of Cabozantinib, Atezolizumab, Abiraterone acetate in prostate cancer, run by Exelixis, active and no longer recruiting.","summary":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC is a phase 3 interventional study registered as NCT04446117 by Exelixis, with 575 participants enrolled, started 2020-10-19 and due to reach its primary completion in 2024-04-19. Interventions recorded: Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone. Conditions listed: Metastatic Prostate Cancer, Prostate Adenocarcinoma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04446117","url":"https://clinicaltrials.gov/study/NCT04446117"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["cabozantinib","atezolizumab","abiraterone","enzalutamide","prednisone"],"companies":["exelixis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04446117-lancet-oncol-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04446117","phase":"3","setting":"A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Exelixis","started":"2020-10-19","startedType":"actual","yearReported":2025,"enrolled":575,"enrolledBasis":"registry","outcomes":[{"endpoint":"Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)","primary":true,"unit":"months","arms":[{"name":"Experimental Arm: Cabozantinib and Atezolizumab","n":200,"value":6.34,"note":"95% CI 6.18 to 8.80; Figures from the ClinicalTrials.gov results section (first posted 2025-12-18), not from a publication"},{"name":"Control Arm: Second NHT","n":200,"value":4.17,"note":"95% CI 3.71 to 5.65"}],"p":"0.0007","source":"https://clinicaltrials.gov/study/NCT04446117?tab=results"},{"endpoint":"Duration of Overall Survival (OS)","primary":true,"unit":"months","arms":[{"name":"Experimental Arm: Cabozantinib and Atezolizumab","n":289,"value":14.78,"note":"95% CI 13.37 to 16.66; Figures from the ClinicalTrials.gov results section (first posted 2025-12-18), not from a publication"},{"name":"Control Arm: Second NHT","n":286,"value":14.98,"note":"95% CI 13.01 to 18.50"}],"p":"0.2956","source":"https://clinicaltrials.gov/study/NCT04446117?tab=results"}]},"route":"/trials/nct04446117/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"}],"company":[{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/"}],"paper":[{"id":"paper-nct04446117-lancet-oncol-2025","kind":"paper","name":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","route":"/key-papers/paper-nct04446117-lancet-oncol-2025/"}]}}